Table 5.
Summary of statistically significant predictive factor findings in advanced non-small-cell lung cancer
| Predictive study | Factor | Conclusion |
|---|---|---|
| Goto et al62 (PRED-4) | Previous therapy | Longer time interval between previous therapy and start of DOC was significantly associated with OS. SD/PD versus CR/PR was significantly associated with response to DOC. |
| Sculier et al41 (PRED-3) | Age | Significant differences not favoring survival with the CIS + CARB + IFOS regimen for women and patients aged ≥60 years. |
| Syrigos et al66 (PRED-2) | Age | In the nonsquamous subgroup analysis, OS for patients aged ≥65 years superior in the CIS + PTX group compared to CIS + GEM group. |
| Syrigos et al66 (PRED-2) | Disease stage | In the nonsquamous subgroup analysis, OS for stage IIIB was superior in the CIS + PTX group compared to CIS + GEM group. |
| Sculier et al41 (PRED-3) | Sex | Significant differences not favoring survival with the CIS + CARB + IFOS regimen for women and patients aged ≥60 years. |
| Ardizzoni et al63 (PRED-2) | Histology | In the meta-analysis, nonsquamous was predictive of lower odds of tumor response and greater risk of mortality for CARB-containing regimens. |
| Syrigos et al66 (PRED-2) | Histology | Histology predicted superior survival for CIS + PTX versus CIS + GEM in patients with nonsquamous non-small-cell lung cancer and shorter survival for CIS + PTX in patients with squamous cell carcinoma. The survival advantage for CIS + PTX was maintained across selected patient subgroups within the nonsquamous group. |
| Soria et al65 (PRED-2) | PS | Subgroup analysis showed a survival advantage in PS 0–1 patients treated with VIN + CIS versus other treatment regimens. |
| Syrigos et al66 (PRED-2) | PS | In the nonsquamous subgroup analysis, OS for PS 0 versus PS 1 was superior in the CIS + PTX group compared with the CIS + GEM group. |
| Syrigos et al66 (PRED-2) | Race | In the nonsquamous subgroup analysis, OS for white patients was superior in the CIS + PTX group versus the CIS + GEM group. |
| Syrigos et al66 (PRED-2) | Smoking | In the nonsquamous subgroup analysis, OS for current or former smokers was superior in the CIS + PTX group as compared with the CIS + GEM group. |
Note: PRED-2–4 represents a rating system for predictive studies where two is high and four is low.
Abbreviations: CARB, carboplatin; CIS, cisplatin; CR, complete response; DOC, docetaxel; GEM, gemcitabine; IFOS, ifosfamide; OS, overall survival; PD, progressive disease; PR, partial response; PS, performance status; PTX, pemetrexed; SD, stable disease; VIN, vinorelbine.